Iovance Biotherapeutics, Inc.
General ticker "IOVA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.3B (TTM average)
Iovance Biotherapeutics, Inc. follows the US Stock Market performance with the rate: 40.6%.
Estimated limits based on current volatility of 4.9%: low 13.76$, high 14.90$
Factors to consider:
- Total employees count: 975 (+16.3%) as of 2025
- US accounted for 98.3% of revenue in the fiscal year ended 2025-12-31
- Top business risk factors: Operating losses, Funding requirements, Manufacturing complexity, Clinical trial delays, Regulatory and compliance
- Current price 155.2% above estimated high
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.90$, 5.34$]
- 2026-12-31 to 2027-12-31 estimated range: [2.23$, 5.92$]
Financial Metrics affecting the IOVA estimates:
- Positive: with PPE of -2.5 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Positive: Investing cash flow per share per price, % of 4.74 > 2.08
- Negative: negative Net income
- Positive: Inventory ratio change, % of -7.50 <= -3.92
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term IOVA quotes
Long-term IOVA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $1.19MM | $164.07MM | $263.50MM |
| Operating Expenses | $461.75MM | $559.35MM | $661.72MM |
| Operating Income | $-460.56MM | $-395.28MM | $-398.21MM |
| Non-Operating Income | $13.04MM | $20.27MM | $5.16MM |
| R&D Expense | $344.08MM | $282.34MM | $300.27MM |
| Income(Loss) | $-447.52MM | $-375.00MM | $-393.05MM |
| Taxes | $-3.48MM | $-2.83MM | $-2.07MM |
| Net Income(Loss)* | $-444.04MM | $-372.18MM | $-390.98MM |
| Stockholders Equity | $584.61MM | $710.40MM | $698.58MM |
| Inventory | $10.37MM | $51.52MM | $51.68MM |
| Assets | $780.35MM | $910.43MM | $913.17MM |
| Operating Cash Flow | $-361.82MM | $-352.98MM | $-302.41MM |
| Capital expenditure | $22.29MM | $11.07MM | $33.84MM |
| Investing Cash Flow | $-155.24MM | $-96.41MM | $47.50MM |
| Financing Cash Flow | $462.96MM | $390.66MM | $300.77MM |
| Earnings Per Share** | $-1.89 | $-1.28 | $-1.09 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.